Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase

How to improve the efficacy and reverse the resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as erlotinib, remains a major challenge in the targeted therapy of lung adenocarcinoma with EGFR-activating mutation. Phosphoglycerate dehydrogenase (PHGDH) is the...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Jiang-Kai, Lei, Hui-Min, Liang, Qian, Tang, Ya-Bin, Zhou, Ye, Wang, Yang, Zhang, Shengzhe, Li, Wen-Bin, Tong, Yunguang, Zhuang, Guanglei, Zhang, Liang, Chen, Hong-Zhuan, Zhu, Liang, Shen, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5858502/
https://www.ncbi.nlm.nih.gov/pubmed/29556358
http://dx.doi.org/10.7150/thno.23177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5858502/
https://www.ncbi.nlm.nih.gov/pubmed/29556358
http://dx.doi.org/10.7150/thno.23177

Ejemplares similares